Gossamer Bio (GOSS) Competitors

Phibro Animal Health (NASDAQ:PAHC) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Do institutionals and insiders hold more shares of PAHC or GOSS?

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 6.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community favor PAHC or GOSS?

Phibro Animal Health received 160 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 67.09% of users gave Gossamer Bio an outperform vote while only 59.81% of users gave Phibro Animal Health an outperform vote.

Company	Underperform	Outperform
Phibro Animal Health	Outperform Votes 317 59.81%	Underperform Votes 213 40.19%
Gossamer Bio	Outperform Votes 157 67.09%	Underperform Votes 77 32.91%

Which has preferable valuation & earnings, PAHC or GOSS?

Phibro Animal Health has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.19B	0.78	$2.42M	$0.78	29.45
Gossamer Bio	$114.70M	2.35	-$179.82M	-$0.23	-5.15

Which has more risk & volatility, PAHC or GOSS?

Phibro Animal Health has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.

Is PAHC or GOSS more profitable?

Phibro Animal Health has a net margin of 1.75% compared to Gossamer Bio's net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	1.75%	25.35%	6.21%
Gossamer Bio	N/A	-127.28%	-22.12%

Does the media favor PAHC or GOSS?

In the previous week, Gossamer Bio had 10 more articles in the media than Phibro Animal Health. MarketBeat recorded 16 mentions for Gossamer Bio and 6 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.57 beat Gossamer Bio's score of 0.58 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Gossamer Bio	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend PAHC or GOSS?

Phibro Animal Health presently has a consensus target price of $20.00, indicating a potential downside of 12.93%. Gossamer Bio has a consensus target price of $7.75, indicating a potential upside of 554.01%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Gossamer Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Phibro Animal Health beats Gossamer Bio on 11 of the 18 factors compared between the two stocks.